Bicara Therapeutics Inc.
BCAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023658
In the last 90 days, Bicara Therapeutics Inc. insiders filed 0 open-market purchases and 7 sales; 171 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Holders of 5% or more of BCAX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Bicara Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 11.50%7.28M shares | – | Mar 2, 20261 filing | Mar 2, 2026 | SEC |
| Invus Global Management, LLC | 13G/A | 9.60%5.22M shares | – | Jul 31, 20251 filing | Jul 31, 2025 | SEC |
| Vestal Point Capital, LP | 13G/A | 6.50%3.58M shares | −2.70 ppfrom 9.20% | May 15, 20253 filings | Feb 17, 2026 | SEC |
| FMR LLC | 13G/A | 6.10%3.35M shares | +1.00 ppfrom 5.10% | Feb 12, 20256 filings | Feb 5, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 5.90%3.24M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Deep Track Capital, LP | 13G | 5.02%2.75M shares | New | Feb 12, 20261 filing | Feb 12, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Bicara Therapeutics Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 2, 20264:25 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 11.50%7.28M shares | – | Feb 26, 2026 | SEC |
| Feb 17, 20264:10 PM ET | Vestal Point Capital, LPand 1 other | 13G/A | 6.50%3.58M shares | −2.70 ppfrom 9.20% | Dec 31, 2025 | SEC |
| Feb 17, 202610:28 AM ET | T. Rowe Price Investment Management, Inc. | 13G | 5.90%3.24M shares | New | Dec 31, 2025 | SEC |
| Feb 12, 20264:19 PM ET | Deep Track Capital, LPand 2 others | 13G | 5.02%2.75M shares | New | Feb 5, 2026 | SEC |
| Feb 5, 20261:16 PM ET | FMR LLCand 1 other | 13G/A | 6.10%3.35M shares | +1.00 ppfrom 5.10% | Dec 31, 2025 | SEC |
| Aug 14, 20253:57 PM ET | Vestal Point Capital, LPand 1 other | 13G/A | 9.20%5.00M shares | +4.10 ppfrom 5.10% | Jun 30, 2025 | SEC |
| Jul 31, 20252:56 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 9.60%5.22M shares | – | Jun 30, 2025 | SEC |
| Jul 17, 202511:11 AM ET | FMR LLCand 1 other | 13G | 5.10%2.76M shares | +0.40 ppfrom 4.70% | Jul 10, 2025 | SEC |
| Jul 17, 202511:08 AM ET | FMR LLCand 1 other | 13G/A | 4.70%2.54M shares | −1.90 ppfrom 6.60%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20254:13 PM ET | Vestal Point Capital, LPand 1 other | 13G | 5.10%2.77M shares | New | Mar 31, 2025 | SEC |
| May 12, 202510:28 AM ET | FMR LLCand 1 other | 13G/A | 6.60%3.61M shares | +1.40 ppfrom 5.20% | Mar 31, 2025 | SEC |
| Mar 3, 20259:14 AM ET | FMR LLCand 1 other | 13G | 5.20%2.80M shares | +1.30 ppfrom 3.90% | Feb 24, 2025 | SEC |
| Feb 12, 20259:16 AM ET | FMR LLCand 1 other | 13G/A | 3.90%2.12M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Bicara Therapeutics Inc. shares.
No Form 144 notices for Bicara Therapeutics Inc. are on file.